

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM598261

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Venture Lending & Leasing VIII, Inc.		09/17/2020	Corporation: MARYLAND
Venture Lending & Leasing IX, Inc.		09/17/2020	Corporation: MARYLAND
RECEIVING PARTY DATA			
Name:	NeuMoDx Molecular, Inc.		
Street Address:	1250 Eisenhower Place		
City:	Ann Arbor		
State/Country:	MICHIGAN		
Postal Code:	48108		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87175050	NEUMODX	
CORRESPONDENCE DATA			
Fax Number:	2483513082		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2487271471		
Email:	byates@jaffelaw.com		
Correspondent Name:	Brenda R. Yates		
Address Line 1:	27777 Franklin Road		
Address Line 2:	Suite 2500		
Address Line 4:	Southfield, MICHIGAN 48034		
ATTORNEY DOCKET NUMBER:	NEUMO-EXIT		
NAME OF SUBMITTER:	Brenda R. Yates		
SIGNATURE:	/bry/		
DATE SIGNED:	09/17/2020		
Total Attachments: 8			
source=NeuMoDx Executed - Release of IP Security Interest-4958346-1#page1.tif			

CH \$40.00 87175050

source=NeuMoDx Executed - Release of IP Security Interest-4958346-1#page2.tif
source=NeuMoDx Executed - Release of IP Security Interest-4958346-1#page3.tif
source=NeuMoDx Executed - Release of IP Security Interest-4958346-1#page4.tif
source=NeuMoDx Executed - Release of IP Security Interest-4958346-1#page5.tif
source=NeuMoDx Executed - Release of IP Security Interest-4958346-1#page6.tif
source=NeuMoDx Executed - Release of IP Security Interest-4958346-1#page7.tif
source=NeuMoDx Executed - Release of IP Security Interest-4958346-1#page8.tif

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

This RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST (“**Release**”) is made and effective as of September 17, 2020 and granted by VENTURE LENDING & LEASING VIII, INC., a Maryland corporation (“**VLL8**”), and VENTURE LENDING & LEASING IX, INC., a Maryland corporation (“**VLL9**”, and, together with VLL8, collectively, the “**Secured Party**”), as lenders under the Loan Agreement referred to below, in favor of NEUMODX MOLECULAR, INC., a Delaware corporation (the “**Grantor**”), and its successors, assigns and legal representatives.

WHEREAS, pursuant to that certain Loan and Security Agreement dated as of September 13, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “**Loan Agreement**”) among the Grantor, as borrower, and the Secured Party, as lender, the Grantor executed and delivered that certain Intellectual Property Security Agreement by and between the Grantor and the Secured Party dated as of September 13, 2018 (the “**IP Security Agreement**” and, together with the Loan Agreement, the “**Security Agreements**”);

WHEREAS, pursuant to the Security Agreements, the Grantor pledged and granted to the Secured Party a security interest in and to all of the right, title and interest of such Grantor in, to and under the IP Collateral (as defined below);

WHEREAS, the IP Security Agreement was recorded with the United States Patent and Trademark Office at Reel 6466, Frame 0255 on September 14, 2018; and

WHEREAS, the Grantor has requested that the Secured Party enter into this Release in order to effectuate, evidence and record the release and reassignment to the Grantor of any and all right, title and interest the Secured Party may have in the IP Collateral pursuant to the Security Agreements.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Secured Party hereby states as follows:

1. Release of Security Interest. Secured Party, on its behalf and on behalf of its successors, legal representatives and assigns, hereby terminates the IP Security Agreement and terminates, releases and discharges any and all security interests that it has pursuant to the Security Agreements in any and all right, title and interest of the Grantor, and reassigns, without recourse or warranty, to the Grantor any and all right, title and interest that it may have, in, to and under the following (collectively, the “**IP Collateral**”):

(a) any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) any and all letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(c) any and all trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, and reissues, extensions or renewals thereof, and the entire goodwill of the business of Grantor conducted with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(d) all licenses or other rights to use any of the Copyrights, the Patents or the Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(e) all amendments, renewals and extensions of any of the Copyrights, the Patents, or the Trademarks;

(f) all rights of any kind whatsoever of such Grantor accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions and otherwise throughout the world;

(g) all proceeds and products of the foregoing, including without limitation, all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing;

(h) any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

(i) any and all claims and causes of action with respect to any of the foregoing, whether occurring before, on or after the date hereof, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Further Assurances. Secured Party agrees, at the Grantor's expense, to take all further actions, and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as the Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.

3. Governing Law. This Release and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Release and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Secured Party has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

VENTURE LENDING & LEASING VIII, LLC,
a Delaware limited liability company

By: Westech Investment Advisors LLC,
a California limited liability company
Its: Managing Member

By: *Maurice Werdegar*
Maurice Werdegar (Sep 10, 2020 11:32 PDF)
Name: Maurice Werdegar
Title: CEO

VENTURE LENDING & LEASING IX, LLC,
a Delaware limited liability company

By: Venture Lending & Leasing IX GP, LLC
Its: Managing Member

By: Westech Investment Advisors LLC
Its: Managing Member

By: *Maurice Werdegar*
Maurice Werdegar (Sep 10, 2020 11:32 PDF)
Name: Maurice Werdegar
Title: CEO

EXHIBIT A

Copyrights

None.

EXHIBIT B**Patents**

NeuMoDx Molecular, Inc.

Patent Status Aug-2020



Docket	Type	Status	Filing Date	Application No.	Publication No.	Patent No.
P01	PRV	Advanced	13-Feb-2012	61/598,240		
P01	PRV2	Advanced	3-Jul-2012	61/667,606		
P01	US1	Issued	13-Feb-2013	13/765,996	US-2013-0210125-A1	9,738,887
P01	US2	Issued	13-Feb-2013	13/766,000	US-2013-0210126-A1	9,433,940
P01	US3	Issued	13-Feb-2013	13/766,009	US-2013-0209326-A1	9,101,930
P01	US4	Issued	30-Jun-2015	14/755,821	US-2015-0298119-A1	9,403,165
P01	US5	Issued	14-Jun-2016	15/182,187	US-2016-0288123-A1	9,452,430
P01	US6	Issued	16-Jan-2017	15/407,160	US-2017-0120243-A1	10,557,132
P01	US7	Published	1-Dec-2017	15/828,721	US-2018-0085749-A1	
P01	PCT	Advanced	13-Feb-2013	PCT/US13/25859	WO2013122995	
P01	AU	Issued	13-Feb-2013	2013221701	2013221701	2013221701
P01	CN	Published	13-Feb-2013	201380009169.7	104254595	
P01	EP	Published	13-Feb-2013	13748851.6	2814942	
P01	JP	Issued	13-Feb-2013	2014-556810		6061313
P02	US1	Issued	13-Feb-2013	13/766,359	US-2013-0210127-A1	9,050,594
P02	US2	Issued	13-Feb-2013	13/766,377	US-2013-0210015-A1	9,339,812
P02	US3	Issued	5-May-2015	14/704,215	US-2015-0232832-A1	9,441,219
P02	US4	Issued	21-Apr-2016	15/134,765	US-2016-0230215-A1	10,041,062
P02	US5	Published	29-Aug-2016	15/249,771	US-2016-0362677-A1	
P02	PCT	Advanced	13-Feb-2013	PCT/US13/25918	WO2013123035	
P02	CN	Issued	13-Feb-2013	201380009286.3	104271765	201380009286.3
P03	PRV	Advanced	25-Oct-2012	61/718,634		
P03	US	Issued	30-Jan-2014	14/168,760	US-2014-0147892-A1	9,382,532
P03	US2	Issued	6-Jun-2016	15/173,880	US-2016-0281080-A1	9,540,636
P03	US3	Issued	29-Nov-2016	15/363,323	US-2017-0073668-A1	10,633,647
P03	US4	Published	20-Mar-2020	16/825,126	US-2020-0216832-A1	
P03	PCT	Advanced	22-Oct-2013	PCT/US13/66162	WO2014066376	
P03	DE	Issued	22-Oct-2013	13849949.6	2912174	2912174
P03	DK	Issued	22-Oct-2013	13849949.6	2912174	2912174
P03	EP	Issued	22-Oct-2013	13849949.6	2912174	EP-B-2912174
P03	ES	Issued	22-Oct-2013	13849949.6	2912174	2912174
P03	FR	Issued	22-Oct-2013	13849949.6	2912174	2912174
P03	GB	Issued	22-Oct-2013	13849949.6	2912174	2912174
P03	IT	Issued	22-Oct-2013	13849949.6	2912174	502019000064944
P03	NO	Issued	22-Oct-2013	13849949.6	2912174	2912174
P03	SE	Issued	22-Oct-2013	13849949.6	2912174	2912174
P04	PRV	Advanced	14-Mar-2013	61/783,265		

P04	PRV2	Advanced	18-Sep-2013	61/879,513		
P04	US	Issued	16-Sep-2014	14/487,808	US-2015-0079666-A1	9,499,896
P04	US2	Issued	19-Oct-2016	15/297,736	US-2017-0036209-A1	10,239,060
P04	US3	Published	12-Feb-2019	16/273,795	US-2019-0176156-A1	
P05	PRV	Advanced	18-Sep-2013	61/879,517		
P05	US	Issued	16-Sep-2014	14/487,837	US-2015-0079667-A1	9,539,576
P05	US2	Issued	29-Nov-2016	15/363,107	US-2017-0072400-A1	10,226,771
P05	US3	Published	31-Jan-2019	16/264,262	US-2019-0160469-A1	
P06	US	Issued	28-Mar-2014	14/229,396	US-2017-0037451-A1	9,637,775
P06	US2	Issued	22-Mar-2017	15/465,796	US-2017-0191115-A1	10,093,963
P06	US3	Published	5-Sep-2018	16/121,864	US-2019-0002959-A1	
P06	PCT	Advanced	30-Mar-2015	PCT/US15/23280	WO2015149057	
P06	CN	Allowed	30-Mar-2015	201580028331.9	106414771	
P06	DE	Issued	30-Mar-2015	15768435.8	3122903	3122903
P06	EP	Issued	30-Mar-2015	15768435.8	3122903	EP3122903
P06	ES	Filing	30-Mar-2015	15768435.8	3122903	
P06	FR	Filing	30-Mar-2015	15768435.8	3122903	
P06	GB	Filing	30-Mar-2015	15768435.8	3122903	
P07	PRV	Advanced	9-Nov-2016	62/419,578		
P07	US	Published	9-Nov-2017	15/808,183	US-2018-0066248-A1	
P08	PRV	Advanced	17-Oct-2014	62/065,500		
P08	US	Issued	4-Feb-2015	14/613,616	US-2015-0151300-A1	9,604,213
P08	US2	Issued	24-Jan-2017	15/413,735	US-2017-0128946-A1	10,010,888
P08	US3	Abandoned	4-Jun-2018	15/996,949	US-2018-0280978-A1	
P09	US	Published	19-Feb-2020	16/794,928	US-2020-0179932-A1	
P09	US2	Published	19-Feb-2020	16/795,003	US-2020-0222906-A1	
P09	US3	Published	7-May-2020	16/868,719	US-2020-0261913-A1	

EXHIBIT C
Trademarks

<u>Description</u>	<u>Registration/Application Number</u>	<u>Registration/Application Date</u>
NeuMoDx	Serial No. 87/175,050	September 19, 2016